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Recently, it has been reported that specific microRNA (miRNA) levels are elevated in serum
and can be used as biomarkers in patients with cardiovascular diseases. However, miRNAs
expression profiles and their sources in pericardial fluid (PF) are unclear.
Methods and Results
The purpose of this study was to identify the levels of miRNAs in PF in relation to those in
the serum in patients undergoing cardiac surgery. Serum (S) and PF from patients undergo-
ing coronary artery bypass graft (CABG) due to stable angina pectoris (sAP) and unstable
AP (uAP) and aortic valve replacement due to aortic stenosis (AS) were analyzed for the
detection of miRNAs. We named these samples S-sAP, S-uAP, S-AS, PF-sAP, PF-uAP,
and PF-AS, respectively. We first measured the levels of miR-423-5p, which was recog-
nized previously as a biomarker for heart failure. miR-423-5p levels were significantly higher
in PF than serum. Although there was no difference in miR-423-5p levels among the PF-
AS, PF-sAP, and PF-uAP, its levels were significantly elevated in S-uAP compared with
those in S-AS and S-sAP. In order to clarify the source of miR-423-5p in PF, we measured
the levels of muscle-enriched miR-133a and vascular-enriched miR-126 and miR-92a in the
same samples. miR-133a levels were significantly higher in serum than in PF, and it was
elevated in S-uAP compared with S-AS. miR-126 level was significantly increased in serum
compared with PF, and the level of miR-92a the similar tendency. miR-423-5p is located in
the first intron ofNSRP1. There is another miRNA, miR-3184, encoded in the opposite direc-
tion in the same region. In vitro experiments indicated that the duplex of miR-423-5p and
miR-3184-3p was more resistant to RNase than the duplex of miR-423-5p and miR-133-3p,
which may help to stabilize miR-423-5p in the PF.
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Conclusions
Our results suggested that miR-423-5p is enriched in PF, and serum miR-423-5p may be
associate with uAP. Its expression pattern was different to that of muscle- and vascular-
enriched miRNAs, miR-133a, miR-126, and miR-92a.
Introduction
MicroRNAs (miRNAs; miRs) are single-stranded, small, non-coding RNAs which act as post-
transcriptional regulators of gene expression [1,2,3]. Each miRNA has been shown to regulate
the expression of multiple genes. Conversely, the expression of each gene can be regulated by
many miRNAs. Thus, well over one-third of human protein-coding genes appear to be regu-
lated by miRNAs [4].
MiRNAs have been identified as key regulators of complex biological processes including
cardiovascular diseases and the number of studies on miRNAs in relation to cardiovascular
pathologies has exponentially increased [5,6,7]. It is known that miRNAs are present in circu-
lating blood in exosomes [8] and microparticles [9]. It has also been reported that miRNAs are
bound to other RNA binding proteins, including nucleophosmin 1 (NPM1), Argonaute2
(Ago2), or by HDL instead of vesicles and are stable in blood [10,11,12]. The levels of specific,
circulating miRNAs have been shown to be associated with various pathological conditions
[13,14], such as heart failure [15] and acute coronary syndrome (ACS) [16,17,18,19,20]. More-
over, accumulating evidence suggests that circulating miRNAs exist not only in serum but also
in other body fluids [21]. From these results, we hypothesized that miRNAs in pericardial fluid
(PF) also may reflect the condition of the heart.
It has been reported that miR-423-5p levels are higher in patients with HF compared with
healthy controls [22,23]. The hearts of patients who need to undergo open heart surgery possi-
bly have repeated ischemic or hemodynamic stresses, which are associated with HF. Therefore,
in this report, we measured the levels of miR-423-5p in serum and PF from patients treated
with a coronary artery bypass graft (CABG) or aortic valve replacement due to aortic stenosis
(AS). We also compared these levels with those of muscle-enriched miR-133a and vascular-
enriched miR-126 and miR-92a in the same samples to address the source of miR-423-5p.
Materials and Methods
Study Population
This study was approved by the Institutional Review Board of Kyoto University Graduate
School and Faculty of Medicine and Kitano Hospital. Written informed consent was given by
all patients or their families in accordance with the Declaration of Helsinki. Diagnosis was
based on the final diagnosis at discharge, which relied on the treating physician’s diagnosis.
Blood and Cardiac Effusion Sampling from Patients
Serum (S) and PF from patients undergoing coronary artery bypass graft (CABG) due to stable
angina pectoris (sAP) and unstable AP (uAP) and aortic valve replacement due to AS were
analyzed for the detection of circulating miRNAs. These samples were designated S-sAP, S-
uAP, S-AS, PF-sAP, PF-uAP, and PF-AS. Venous blood obtained on admission was put into a
commonly used test tube containing polyolefin resin for serum separation. The tube was
microRNA-423-5p in Pericardial Fluid
PLOS ONE | DOI:10.1371/journal.pone.0142904 November 12, 2015 2 / 12
centrifuged at 12,000 × g for 10 min. PF samples were collected during operation. The serum
and PF was aliquoted and stored at -80°C until assayed.
Quantification of Circulationg miRNAs
As described in detail previously [20], we quantified circulating miRNAs. Total RNA was
extracted from 350μL of serum and PF, using TRIzol LS reagent (Invitrogen, Carlsbad, USA).
microRNAs were quantified using quantitative reverse-transcriptase-polymerase chain reac-
tion (qRT-PCR) TaqMan MicroRNA Assays (Applied Biosysetms, Foster city, USA) and a
7900HT Fast Real-Time PCR System (Applied Biosystems) in accordance with the manufac-
turer’s instructions. Total RNA (100ng) was used to synthesize miR-133a-specific cDNA, and
10 ng of total RNA was used to synthesize miR-423-5p-, miR-126-, and miR-92a-specific
cDNAs using the TaqMan microRNA assay. To evaluate miRNA expression levels, PCR was
carried out in duplicate. Each miRNA level was normalized using exogenous cel-miR-39 and
quantified by the 2-ΔCt method. When the Ct value of cel-miR-39 could not be determined or
was more than 31, the samples were thought to be degradated and were excluded. If the Ct
value of the target miRNA could not be determined, the expression level was regarded as 0.
Evaluation of the Stability of Double Strand RNAs
RNA oligonucleotides were dissolved at 5μM in RNAse free water and annealed. RNaseA
(Roche, Basel, Switzerland) was added to the annealed RNA oligonucleotides at a concentra-
tion of 100ug/ml. Total RNA was extracted from RNA solutions before and 5 and 20minutes
after the addition of RNaseA using TRIzol LS reagent (Invitrogen), Each miRNA level was nor-
malized with exogenous cel-miR-39 and quantified by the 2-ΔΔCt method. Total RNA (100 ng)
was used to synthesize miR-423-5p-specific cDNA using TaqMan microRNA assay. For the
measurement of each miRNA, 7900HT Fast Real-Time PCR System was used, as described for





Purification of Neonatal Mouse Cardiac Myocytes and Fibroblasts
We purified neonatal mouse cardiomyocytes and cardiac fibroblasts in according with previous
reports [24,25]. Mice were maintained on a 12-h light/dark cycle, fed a normal laboratory diet
ad libitum, sacrificed by decapitation. Mouse ventricles were isolated from 1-day-old C57BL/6
mice and dispersed in digestion buffer containing 1.3 mg/mL pancreatin (P3292; Sigma, St.
Louis, USA) and 0.45 mg/mL collagenase type II (17101–015; Gibco1, Invitrogen Carlsbad,
USA). Collected cells were washed in a 3:1 mixture of Dulbecco’s modified Eagle’s medium
(DMEM) and medium 199 (Gibco1) supplemented with 10% horse serum (Gibco1), 10%
fetal bovine serum (FBS; Sigma, 172012), 100 units/mL penicillin (Gibco1), 100 μg/mL strep-
tomycin (Gibco1), and 292 μg/mL L-glutamine (Gibco1). The cells were centrifuged at 280 ×g
for 5 min, mixed in serum-free DMEM and stained for fluorescence-activated cell sorting
(FACS) analyses. MitoTracker1 Green FM (M7514; Invitrogen, Carlsbad, USA) solution was
utilized to identify cardiac myocytes, and anti-mouse Thy-1.2 antibody conjugated with allo-
phycocyanin (APC) (17-0902-81; eBioscience, San Diego, USA) was used to stain cardiac fibro-
blasts. FACS system (BD FACSAria™ II; Becton Dickinson, Franklin Lakes, USA) was used to
detect MitoTracker Green and APC. This investigation conformed to the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes of Health (NIH
microRNA-423-5p in Pericardial Fluid
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Publication No. 85–23, revised 1996). All animal care, experiments, and methods were
approved by the Animal Care and Use Committees of Kyoto University Graduate School of
Medicine (MedKyo15167).
Statistical Analysis
Data are presented as mean ± SD for patient characteristics, as median and interquartile ranges
for human samples and as mean ± SEM in in vitro experiments, unless otherwise described.
Patient characteristics were assessed using one-way ANOVA and chi-square test. For statistical
comparisons, Wilcoxon test (two paired groups), Spearman test (two groups), or Kruskal-
Walllis test (three groups) with Dunn’s multiple comparisons test were used in for human sam-
ples. For statistical comparisons for in vitro experiments, Student’s t test (two unpaired group)
or ANOVA (three or more groups) with Turkey’s post hoc test were used. A probability value
<0.05 was considered to indicate statistical significance. When the Ct value of cel-miR-39
could not be determined or was more than 31, the samples were thought to be degraded and
were excluded. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Soft-
ware, Inc., San Diego, USA) or JMP Pro version 11 statistical packages (SAS Institue Inc., Cary,
USA).
Results
miR-423-5p is Enriched in the PF and Is Elevated in S-uAP Compared
with S-sAP and S-AS
To clarify the expression levels of miRNAs in PF in relation with those in the serum in patients
undergoing cardiac surgery, serum and PF from patients undergoing CABG due to sAP
(n = 16) and uAP (n = 13) and aortic valve replacement due to AS (n = 13) were analyzed.
Accordingly, we designated these samples S-sAP, S-uAP, S-AS, PF-sAP, PF-uAP, and PF-AS.
Quantitative real-time PCR methodologies have been widely applied in miRNA research, espe-
cially for assessing low levels of serum miRNAs. To date, the most widely used and successful
approach in terms of specificity and sensitivity is a two-step approach using looped miRNA-
specific reverse transcription primers and TaqMan probes [26]. Therefore, we applied this sys-
tem to determine the levels of miRNAs in our patients. Baseline characteristics of the patients
according to their disease condition are summarized in Table 1. The aspartate aminotransfer-
ase and alanine aminotransferase levels of the patients with uAP were significantly higher than
in those with sAP and AS. The proportion of patients reporting regular alcohol intake was also
significantly elevated in patients with uAP compared with the other groups. We first measured
the levels of miR-423-5p, which was recognized previously as a biomarker for heart failure. We
found that miR-423-5p levels were significantly higher in PF compared with serum (Fig 1A).
Although there was no difference in the levels of miR-423-5p among PF-AS, PF-sAP, and PF-
uAP, (Fig 1B), miR-423-5p levels were significantly higher in S-uAP than those in S-AS and S-
sAP (Fig 1C).
Muscle-Enriched and Vascular-Enriched miRNAs Are Not Elevated in
PF
In order to clarify the source of miR-423-5p, we also measured the levels of muscle-enriched
miR-133a and vascular-enriched miR-126 and miR-92a in the same samples. The levels of
miR-126 and miR-133a were significantly elevated in the serum compared with PF, and miR-
92a showed a similar tendency (P = 0.12) (Fig 2A, 2C and 2E). miR-133a and miR-92a levels
were significantly elevated in S-uAP compared with S-AS (Fig 2B and 2F). There was no
microRNA-423-5p in Pericardial Fluid
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difference in the levels of miR-126 among PF-AS, PF-sAP, and PF-uAP, (Fig 2D), and there
was no difference in miR-133a, miR-92a, and miR-126 levels among PF-uAP, PF-sAP and
PF-AS (S1 Fig). Elevation of miR-133a in S-uAP was consistent with our previous results that
the serum levels of miR-133 were elevated in patients with myocardial injury [20]. We then
sought to determine which cells express miR-423-5p in the heart. Cardiomyocytes and cardiac
fibroblasts were isolated by FACS from neonatal mice hearts [24,25]. The expression levels of
miR-423-5p were significantly higher in cardiomyocytes than in fibroblasts (Fig 2G).
miR-423-5p and miR-3184 Are Encoded in the Same Intron in the
Opposite Direction
miR-423-5p is located within the intron of nuclear speckle splicing regulatory protein 1
(NSRP1). There is also another miRNA, miR-3184, encoded in the opposite direction at the
same region (Fig 3A). The complementarity between miR-423-5p are miR-3184-3p is complete,
Table 1. Baseline Characteristics of Patients with sAP, uAP, and AS.
Stable AP (N = 16) Unstable AP (N = 13) AS (N = 16) p value
Age (yr), N = 45 71.4±10.0 71.6±3.6 71.8±13.1 n.s
Gender (male/female), N = 45 10/6 10/3 9/7 n.s
Height (cm), N = 45 158.9±8.6 162.5±8.0 159.4±8.2 n.s
Weight (kg), N-45 61.3±12.6 65.5±12.9 61.2±11.5 n.s
LVDd (mm), N = 42 48.9±8.4 52.0±6.1 47.7±6.5 n.s
LVDs (mm), N = 42 35.2±10.2 38.2±8.5 33.1±6.2 n.s
LVEF (%), N = 42 54.9±11.8 50.2±15.8 58.9±7.7 n.s
Diabetes mellitus (%), N = 45 50.0 46.2 43.8 n.s
Hypertension (%), N = 45 87.5 92.3 68.8 n.s
Dyslipidemia (%), N = 45 81.3 69.2 62.5 n.s
Active Smoker (%), N = 43 6.7 16.7 6.3 n.s
Alcohol (%), N = 41 46.7 80.0 25.0 0.02
ACEI or ARB (%), N = 45 62.5 69.2 56.3 n.s
β-blocker (%), N = 45 25.0 30.8 31.3 n.s
Oral hypoglycemic drug (%), N = 45 37.5 23.1 31.3 n.s
Insulin (%), N = 45 18.8 15.4 12.5 n.s
Statin or probucol (%), N = 45 56.3 53.9 43.8 n.s
AST (IU/L), N = 42 21.6±7.2 32.6±14.8 18.9±6.4 <0.01
ALT (IU/L), N = 42 17.4±10.0 28.8±17.5 13.3±7.2 <0.01
LDL-cho (mg/dl), N = 42 110.6±33.9 113.4±35.0 104.0±38.1 n.s
CK (mg/dl), N = 44 73.7±34.9 160.0±165.1 111.8±103.8 n.s
Cr (mg/dl), N = 42 1.9±1.7 1.5±2.2 3.4±3.7 n.s
eGFR (ml/min/1.73m2), N = 42 40.0±24.3 57.8±20.6 44.1±33.0 n.s
Hb (g/dl), N = 44 12.4±2.0 12.7±2.1 11.6±1.7 n.s
log2BNP (pg/ml), N = 42 6.4±2.0 7.3±2.2 7.8±2.7 n.s
BS (mg/dl), N = 44 120.4±47.7 140.2±49.2 146.0±61.7 n.s
HbA1c (%), N = 41 5.9±1.2 6.4±1.9 5.9±1.9 n.s
sAP, stable angina pectoris; uAP, unstable angina pectoris; AS, aortic stenosis; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-
systolic dimension; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; LDL-cho, low density lipoprotein; CK, creatine phosphokinase; eGFR, estimated glomerular
ﬁltration rate; Hb, hemoglobin; BNP brain natriuretic peptide; BS, blood sugar; HbA1c, and hemoglobin A1c. All values are expressed as mean ± SD.
doi:10.1371/journal.pone.0142904.t001
microRNA-423-5p in Pericardial Fluid
PLOS ONE | DOI:10.1371/journal.pone.0142904 November 12, 2015 5 / 12
Fig 1. SerummiR-423-5p levels are elavated in the patients with unstable angina pectoris (uAP)
compared with stable angina pectoris (sAP) and aortic stenosis (AS). (A) Expression levels of miR-423-
5p in the pericardial fluid (PF) and serum. (B) Expression levels of miR-423-5p in serum of patients with AS,
sAP and uAP. miR-423-5p levels were using exogenous cel-miR-39. Data are presented as mean ± SD.
*P<0.05. **P<0.01. (C) Expression levels of miR-423-5p in the PF of patients with AS, sAP and uAP. miR-
423-5p levels were normalized using exogenous cel-miR-39. Data are presented as median and interquartile
range. *P<0.05.
doi:10.1371/journal.pone.0142904.g001
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Fig 2. Muscle-enriched and vascular-enrichedmiRNAs are not elevated in PF compared with serum.
(A) Expression levels of miR-133a in serum and PF, (B) Expression levels of miR-133a in the serum of
patients with aortic stenosis (AS), stable angina pectoris (sAP) and unstable angina pectoris (uAP), (C)
Expression levels of miR-92a in serum and PF, (D) Expression levels of miR-92a in serum of patients with
AS, sAP and uAP, (E) Expression levels of miR-126 in serum and PF, (F) Expression levels of miR-126 in the
microRNA-423-5p in Pericardial Fluid
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whereas that between miR-3184-5p and miR-423-3p is lower. The complementarity between
miR-423-5p and -3p is almost half of that of miR-423-5p and miR-3184-3p (Fig 3B). It was
reported that complementary miRNA pairs form miRNA:miRNA duplexes [27]. We hypothe-
sized that miR-423-5p and miR-3184-3p may formmiR-423-5p:miR-3184-3p RNA duplexes
and analyzed the stability of miR-423-5p:miR-3184-3p duplexes. We annealed miR-423-5p with
miR-3184-3p or miR-133a-3p and compared the levels of miR-423-5p using RNaseA treatment
for different time periods (Fig 3C). The levels of miR-423-5p were still high at 5 and 20 minutes
serum of patients with AS, sAP and uAP. Each miRNA level was normalized using exogenous cel-miR-39.
Data are presented as median and interquartile range. *P<0.05. **P<0.01. (G) Expression levels of miR-
423-5p in cardiomyocytes and fibroblasts from neonatal mice hearts, n = 4. miR-423-5p was normalized
using U6. Data are presented as mean ± SEM. * p<0.05
doi:10.1371/journal.pone.0142904.g002
Fig 3. miR-423-5p andmiR-3184-3p are complementary to each other. (A) Localization of nuclear speckle splicing regulatory protein 1 (NSRP1) on
chromosome 17q11.2. MiR-423-5p is located in intron1 of NSRP1. MiR-423-5p and miR-3184-3p are encoded in opposite direction in the same region. (B)
Sequence alignment between miR-423-5p and miR-3184-3p, miR-423-5p and miR-423-3p, and miR-3184-5p and miR-423-5p (C) miR-423-5p:miR-3184-3p
and miR-423-5p:miR-133a were treated with 100μg/ml RNase A, and the expression level of miR-423-5p was measured at the indicated time points (n = 3).
Data are presented as mean ± SEM. *p<0.05, **p<0.01 (D) The correlation between the expression levels of miR-423-5p and miR-3184-3p in PF (n = 31).
Each miRNAs was normalized using exogenous cel-miR-39.
doi:10.1371/journal.pone.0142904.g003
microRNA-423-5p in Pericardial Fluid
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after the addition of RNase A when an RNA duplex of miR-423-5p:miR-3184-3p formed, which
was more stable than that of miR-423-5p:miR-133a-3p. Moreover, the levels of miR-423-5p in
PF had a tendency to correlate to the levels of miR-3184-3p (Fig 3D, r = 0.35, p = 0.0515). These
results suggested that miR-3184-3p may help to stabilize miR-423-5p in the PF.
Discussion
In this report, we analyzed miRNA levels in PF in association with those in the serum. miR-
423-5p levels were significantly higher in PF than serum. Although there was no difference in
miR-423-5p levels among the PF-AS, PF-sAP, and PF-uAP, its levels were significantly elevated
in S-uAP compared with those in S-AS and S-sAP. In order to clarify the source of miR-423-
5p, we measured the levels of muscle-enriched miR-133a and vascular-enriched miR-126 and
miR-92a in the same samples. However, their expression patterns were distinct from miRNA-
423-5p. We noticed that miR-423-5p and miR-3184-3p are located within the same region of
NSRP1 intron in the opposite direction, and RNA duplexes may be formed by these miRNAs.
Although the biological function of miR-423-5p is still unknown, we found that miR-423-
5p levels were significantly higher in S-uAP than those in S-sAP and S-AS. This result indicated
that circulating miR-423-5p may reflect the disease status of cardiac ischemia. It has been
reported that miR-423-5p levels are higher in patients with HF compared with healthy controls
and correlated with NT-proBNP (BNP) and EF [22]. Other reports also revealed that four cir-
culating miRNAs (miR-423-5p, miR-320a, miR-22 and miR-92b) were significantly increased
in patients with systolic HF, and a score based on the levels of these four miRs correlated with
clinical parameters in patients with systolic HF [23]. However, there was no correlation
between serum or PF levels of miR-423-5p and BNP in our samples (S2 Fig). This may be
because our samples were obtained from patients before operations and most of the patients
were already controlled by medications. As a result, BNP levels in our samples were not as high
as those observed in acute decompensated HF.
Some miRNAs have been shown to exhibit tissue-specific expression, such as miR-133a,
miR-126, or miR-92a. On the other hand, miR-423-5p was shown to be ubiquitously expressed
in diverse tissues in porcine [28]. Although the origin of PF is unclear, many substances in PF
are reported to be carried from coronary sinus through the capillary network [29,30]. miR-
423-5p was reported to show significant differences in the transcoronary gradient in HF
patients compared with controls. This result suggested that miR-423-5p is produced and/or
released by the myocardium in HF patients [31]. Although miR-423-5p is enriched in cardio-
myocytes compared with fibroblasts in neonatal mouse heart, the reason why they are elevated
in the samples of patients with uAP is still unknown.
In our study, miR-423-5p was detected with high abundance in PF compared with serum.
We speculate that miR-423-5p may form a duplex with miR-3184-3p, which protects it from
degradation. Currently, it is not possible to identify the existence of duplex RNA in vivo.
Advanced techniques in the future may enable us to understand the function of the unique
localization of miR-423 and miR-3184.
Circulating miRNAs have been reported to be useful as biomarkers of numerous diseases.
Weber et al. investigated the distribution of miRNAs in 12 human body fluids such as saliva,
urine, and pleural effusion. The composition of miRNAs varied among those samples [32].
Among them, it is reported that several miRNAs in urine samples had potential diagnostic bio-
markers of prostate cancer. [33,34]. Kuosmanen et al. made the first report of the profile of
miRNAs in PF of patients with HF [35]. They reported that miR-16 and miR-21 were detected
at high levels from the PF samples. As shown in S3 Fig, miR-16 and miR-21 were detected at
high levels. Although it is impossible to compare different miRNAs in absolute values by using
microRNA-423-5p in Pericardial Fluid
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the TaqMan microRNA assay, miR-16 and miR-21 seem to be present at high levels in PF.
They could not detect any miRNAs that reflected the clinical features of their patients. How-
ever, Fujita et al. showed that angiogenic growth factors in PF were significantly higher in
patients with ischemic heart diseases than in those with non-ischemic heart diseases [36]. They
also showed that BNP levels in PF were associated with left ventricular dysfunction [37]. There-
fore, it was hypothesized that there may be functional miRNAs in PF, and some of them may
be utilized to reflect clinical status. Although we were not able to detect the disease-specific
miRNAs in PF so far, in depth analyses of miRNAs by miRNA microarrays or RNA sequence
may allow us to find miRNAs that are useful to detect the patients’ heart condition in the
future.
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